I

    InflaRx N.V. (IFRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.13
    -0.10 (-4.48%)

    Market Cap: $328.63M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(22/36)
    Avg Surprise
    -13.76%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.08 - $-0.03
    5 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate Drift
    90d ago$-0.04+23.1%
    60d ago$-0.05-1.0%
    30d ago$-0.05-1.0%
    7d ago$-0.05-1.0%
    Current$-0.05
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.01
    Range$-0.05 - $0.01
    5 analysts
    Revenue Consensus
    $-9300
    Range$-9300 - $-9300
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.01---
    Sep 26EST
    		-$-0.05---
    Jun 26
    		$-0.11$-0.08-37.50%Miss+54.2%
    Mar 26
    		$-0.08N/A+55.56%Beat+38.5%
    Dec 25
    		$-0.15$-0.15+0.00%Beat-66.7%
    Sep 25
    		$-0.18$-0.12-50.00%Miss+40.0%
    Jun 25
    		$-0.24$-0.24+0.00%Beat+0.0%
    Mar 25
    		$-0.13$-0.18+27.78%Beat+23.5%
    Dec 24
    		$-0.09N/A+64.19%Beat+66.7%
    Sep 24
    		$-0.30$-0.25-20.00%Miss-130.8%
    Jun 24
    		$-0.24$-0.18-33.33%Miss-71.4%
    Mar 24
    		$-0.17$-0.22+22.73%Beat+32.0%
    Dec 23
    		$-0.27$-0.18-50.00%Miss-50.0%
    Sep 23
    		$-0.13$-0.23+43.48%Beat+27.8%
    Jun 23
    		$-0.14N/A+56.25%Beat-1500.0%
    Mar 23
    		$-0.25$-0.27+7.41%Beat+21.9%
    Dec 22
    		$-0.18$-0.25+28.00%Beat+43.8%
    Sep 22
    		$-0.18$-0.35+48.57%Beat+33.3%
    Jun 22
    		$0.01N/A+103.13%Beat+103.0%
    Mar 22
    		$-0.32$-0.34+5.88%Beat-77.8%
    Dec 21
    		$-0.32$-0.22-45.45%Miss+0.0%
    Sep 21
    		$-0.27$-0.34+20.59%Beat-8.0%
    Jun 21
    		$-0.33$-0.21-57.14%Miss+13.2%
    Mar 21
    		$-0.18$-0.22+18.18%Beat+43.8%
    Dec 20
    		$-0.32$-0.22-45.45%Miss+38.5%
    Sep 20
    		$-0.25$-0.33+24.24%Beat+55.4%
    Jun 20
    		$-0.38$-0.36-5.56%Miss+35.6%
    Mar 20
    		$-0.32$-0.52+38.46%Beat+15.8%
    Dec 19
    		$-0.52$-0.60+13.33%Beat-33.3%
    Sep 19
    		$-0.56$-0.54-3.70%Miss-86.7%
    Jun 19
    		$-0.59$-0.46-28.26%Miss-490.0%
    Mar 19
    		$-0.38$-0.51+25.49%Beat+5.0%
    Dec 18
    		$-0.39$-0.36-8.33%Miss+81.9%
    Sep 18
    		$-0.30$-0.33+9.09%Beat+99.8%
    Jun 18
    		$-0.10N/A+67.74%Beat+37.5%
    Mar 18
    		$-0.40$-0.28-42.86%Miss-
    Dec 17
    		$-2.16$-0.25-764.00%Miss-
    Sep 17
    		$-144.00$-171.38+15.98%Beat-
    Mar 17
    		$-0.16$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.52EV/EBITDA0.50x
    Price/FCF-8.98xFCF Yield-11.13%
    Profitability
    Profit Margin0.00%Operating Margin352965.00%
    ROE-38.50%ROIC-30.00%
    Financial Health
    Debt/Equity0.00xInterest Coverage-720.39x
    Current Ratio8.22xQuick Ratio8.22x
    Trading Statistics
    Beta2.52Avg Volume1.03M
    52-Week High$2.9552-Week Low$0.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.20
    SMA 20$2.06
    SMA 50$1.99
    SMA 200$1.49
    EMA 10$2.18
    EMA 20$2.10
    EMA 50$2.00
    EMA 200$1.65

    MACD

    Line: 0.10Signal: 0.08Hist: 0.02

    ADX

    ADX: 30.8+DI: 26.3-DI: 17.4

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down4.0
    PSAR$2.07

    Bollinger Bands

    Upper Band$2.45
    Lower Band$1.67
    %B Position3819%(Upper)
    Band Width0.59

    RSI (14-Day)

    Neutral
    53.2

    Momentum Oscillators

    Stoch %K52.1
    Stoch %D69.0
    Williams %R-63.8
    ROC (10d)2.9%
    Momentum0.06
    CCI (20d)45.3
    MFI (14d)70.8

    Volatility Measures

    ATR (14d)$0.15(7.3%)
    StdDev (20d)0.20
    Hist Vol91.3%(High)

    Volume Flow

    VWAP$2.15
    OBV148.6M
    AD Line-37.6M
    CMF (20d)0.184

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.4x(Low)
    VWMA (20d)$2.13

    Pivot Points

    R3$2.49
    R2$2.43
    R1$2.33
    Pivot Point$2.27
    S1$2.17
    S2$2.11
    S3$2.01

    Advanced Oscillators

    TSI20.07
    Ultimate Osc55.8
    KST161.09

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$-33,931$23,830$39,432$0$-423$123,819$6,357$36,037$2,286$60,803
    Cost of Revenue$0$88,615$4.86M$333$2.40M$9,291$2.82M$-72,555$348,153$220,521$277,146$255,116
    Gross Profit$0$-88,615$-4,892,342$23,497$-2,360,151$-9,291$-2,821,343$196,374$-341,796$-184,484$-274,860$-194,313
    Operating Expenses$7.05M$7.21M$7.96M$9.50M$10.47M$13.00M$6.94M$15.56M$15.05M$12.30M$13.03M$10.96M
    R&D$4.74M$4.17M$5.26M$6.24M$7.20M$7.02M$6.91M$11.14M$10.02M$7.30M$8.07M$7.31M
    SG&A$2.55M$3.18M$4.56M$2.62M$3.70M$5.06M$5.67M$2.81M$3.50M$3.58M$4.17M$2.90M
    Operating Income$-7,051,045$-7,208,150$-12,856,841$-9,477,005$-12,825,155$-13,005,139$-9,763,471$-15,360,039$-15,396,663$-12,488,690$-13,306,235$-11,150,854
    Interest Income$770,661$334,768$391,309$438,134$522,221$493,764$674,338$768,326$848,243$908,426$1.07M$1.19M
    Interest Expense$14,643$15,052$15,890$14,359$3,355$4,086$4,779$5,032$8,732$5,027$21,671$0
    Income Before Tax$-10,648,484$-5,592,649$-10,642,392$-12,248,808$-14,323,438$-8,314,025$-5,111,772$-17,444,437$-12,691,014$-9,657,236$-15,930,157$-7,451,410
    Income Tax Expense$0$0$0$12,282$0$0$0$5,217$-1$2$-2$4,897
    Net Income$-10,648,484$-5,592,649$-10,642,393$-12,261,089$-14,416,271$-8,314,027$-5,111,772$-17,449,654$-13,845,741$-9,657,236$-15,930,156$-7,451,410
    EBITDA$-10,633,841$-5,490,658$-10,534,064$-12,134,656$-14,205,083$-8,196,138$-4,996,256$-17,327,960$-12,543,299$-9,528,655$-15,774,473$-7,307,593
    EBITN/A$-5,577,840$-10,624,953$-12,234,449$-14,320,083$-8,309,939$-5,106,993$-17,439,405$-12,682,282$-9,652,604$-15,910,005$-7,446,513
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IFRX

    News

    InflaRx Announces Participation in September Investor Conferences

    InflaRx N.V. (Nasdaq: IFRX) announced its participation in two investor conferences in September 2026: the Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The biopharmaceutical company will engage in fireside chats and presentations, and conduct one-on-one investor meetings at both events. Links to live streams and replays will be made available for interested participants.

    GlobeNewswire•8/20/26•
    Neutral

    Commodore Capital reports 5%+ stake in InflaRx (IFRX)

    Commodore Capital LP, along with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, has reported a beneficial ownership of 7,475,000 ordinary shares in InflaRx N.V. (IFRX), representing a 5.1% stake. This ownership is based on 147,368,221 shares outstanding as of June 30, 2026. The filing indicates shared voting and dispositive power over these shares, with no sole authority.

    Stock Titan•8/17/26•
    Neutral

    EDGAR Filing Documents for 0001140361-26-033149

    This SEC EDGAR filing details a Form 424B5 prospectus for InflaRx N.V., filed on August 14, 2026. The document, with SEC Accession No. 0001140361-26-033149, includes six associated files, such as the prospectus and graphic elements. It also provides the company's mailing and business addresses, CIK, EIN, and SIC code for Pharmaceutical Preparations.

    SEC.gov•8/14/26•
    Neutral

    InflaRx (IFRX) investors report 15.6% and 12.5% stakes in updated 13G/A

    Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an updated Schedule 13G/A, reporting significant beneficial ownership in InflaRx N.V. Montanova Capital and Aaron Cowen each report a 15.6% stake, while Averill Master Fund, Ltd. holds 12.5% of the common shares. All reported shares are directly owned by advisory clients of Montanova Capital, with the entities disclaiming beneficial ownership beyond their pecuniary interest.

    Stock Titan•8/14/26•
    Neutral

    Sirenia Capital (IFRX) discloses 8.9M InflaRx shares, a 6.1% ownership stake

    Sirenia Capital Management LP and Alex Silverstein have disclosed a beneficial ownership of 8,911,348 ordinary shares in InflaRx N.V. (IFRX), representing a 6.1% stake in the company. This disclosure was made via a Schedule 13G filing. The shares are held by investment funds managed by Sirenia, and both parties share voting and dispositive power over these shares.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About IFRX

    Does IFRX pay dividends?
    InflaRx N.V. (IFRX) does not currently pay a regular dividend.
    What is IFRX's market cap?
    InflaRx N.V. (IFRX) has a market capitalization of $328.63M with a current stock price of $2.13.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In